ADC
CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
July 29, 2024Research and Development ADC, CHMP, Merck, Oncology, Urology, keytruda, metastatic urothelial carcinoma, unresectable urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 therapy, in combination with Padcev …
Abenza announces investment in bioconjugation and ADC capabilities
March 28, 2024Business Services ADC, Abenza, Pharmacy, bioconjugation, investment
Abenza has announced a major investment in bioconjugation and antibody drug conjugate (ADC) capabilities in response to an increasing industry …
Lonza to acquire Synaffix to strengthen ADC development
June 1, 2023Medical Communications ADC, Lonza, Oncology, Synaffix, drug development
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company …
Astellas and Sony enter collaborative research agreement
May 16, 2023Research and Development ADC, Astellas Pharma, Oncology, Sony, research agreement
Sony and Astellas Pharma have announced that they have entered into a collaborative research agreement in an attempt to discover …
LaNova Medicines and AstraZeneca sign global exclusive license agreement for preclinical ADC
May 15, 2023Research and Development ADC, AstraZeneca, LaNova Medicines, License Agreement, Oncology
Chinese biotechnology company LaNova Medicines and UK-based pharma company AstraZeneca have announced that they have signed a global exclusive license …
LegoChem and Iksuda expand License Agreement for antibody drug conjugates
June 22, 2021Manufacturing and Production ADC, License Agreement, deal, technology
Iksuda Therapeutics, a developer of antibody drug conjugates (ADCs), has announced the expansion of the research collaboration and License Agreement …
Takeda buys license to ImmunoGen cancer tech
March 24, 2015Research and Development, Sales and Marketing ADC, Immunogen, Takeda, antibody, conjugate, merger
Takeda has licensed the exclusive rights to use ImmunoGen’s popular antibody-drug conjugate (ADC) technology to develop new cancer drugs. The …
AstraZeneca pays $460m for cancer specialists
October 15, 2013Research and Development, Sales and Marketing ADC, AstraZeneca, Cancer, MedImmune, spirogen
AstraZeneca’s biologics arm MedImmune has bought cancer biotech firm Spirogen and set up a licensing deal with ADC Therapeutics for …
Synthon opens ADC plant in the Netherlands
January 29, 2013Manufacturing and Production ADC, Synthon
Synthon Biopharmaceuticals says it has opened officially opened a new antibody-drug conjugate (ADC) manufacturing facility in Nijmegen, the Netherlands. The …
Lonza earmarks $15m for ADC plant expansion
January 14, 2013Manufacturing and Production ADC, API, Lonza, Novasep
Swiss contract manufacturer Lonza has said it will invest around 14 million francs ($15m) in new capacity for antibody drug …
Piramal opens ADC plant in Scotland
April 2, 2012Manufacturing and Production ADC, Abbott, Piramel
India’s Piramal Healthcare has officially opened a new production unit to make antibody-drug conjugates at its facility in Grangemouth, Scotland. …
Latest content
FibroFind appoints Lee Borthwick as CEO
